DNA Damage Repair Pathways in Prostate Cancer: A Narrative Review of Molecular Mechanisms, Emerging Biomarkers and Therapeutic Targets in Precision Oncology

被引:3
|
作者
Grypari, Ioanna-Maria [1 ]
Tzelepi, Vasiliki [2 ]
Gyftopoulos, Kostis [3 ]
机构
[1] Natl Kapodistrian Univ Athens, Aretaie Univ Hosp, Cytol Dept, Athens 11528, Greece
[2] Univ Patras, Sch Med, Dept Pathol, Patras 26504, Greece
[3] Univ Patras, Sch Med, Dept Anat, Patras 26504, Greece
关键词
prostate cancer; DNA damage repair; homologous recombination deficiency; mismatch repair pathway; biomarkers; MICROSATELLITE INSTABILITY; INTRADUCTAL CARCINOMA; PROMOTER HYPERMETHYLATION; RADICAL PROSTATECTOMY; PARP; INHIBITORS; THERAPIES; GERMLINE; RISK; PD-1;
D O I
10.3390/ijms241411418
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prostate cancer (PCa) has a distinct molecular signature, including characteristic chromosomal translocations, gene deletions and defective DNA damage repair mechanisms. One crucial pathway involved is homologous recombination deficiency (HRD) and it is found in almost 20% of metastatic castrate-resistant PCa (mCRPC). Inherited/germline mutations are associated with a hereditary predisposition to early PCa development and aggressive behavior. BRCA2, ATM and CHECK2 are the most frequently HRD-mutated genes. BRCA2-mutated tumors have unfavorable clinical and pathological characteristics, such as intraductal carcinoma. PARP inhibitors, due to the induction of synthetic lethality, have been therapeutically approved for mCRPC with HRD alterations. Mutations are detected in metastatic tissue, while a liquid biopsy is utilized during follow-up, recognizing acquired resistance mechanisms. The mismatch repair (MMR) pathway is another DNA repair mechanism implicated in carcinogenesis, although only 5% of metastatic PCa is affected. It is associated with aggressive disease. PD-1 inhibitors have been used in MMR-deficient tumors; thus, the MMR status should be tested in all metastatic PCa cases. A surrogate marker of defective DNA repair mechanisms is the tumor mutational burden. PDL-1 expression and intratumoral lymphocytes have ambivalent predictive value. Few experimental molecules have been so far proposed as potential biomarkers. Future research may further elucidate the role of DNA damage pathways in PCa, revealing new therapeutic targets and predictive biomarkers.
引用
收藏
页数:26
相关论文
共 50 条
  • [41] Investigating underlying molecular mechanisms, signaling pathways, emerging therapeutic approaches in pancreatic cancer
    Mustafa, Mohd
    Abbas, Kashif
    Alam, Mudassir
    Habib, Safia
    Hasan, Gulam Mustafa
    Islam, Sidra
    Shamsi, Anas
    Hassan, Imtaiyaz
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [42] Molecular Mechanisms of Cancer Drug Resistance: Emerging Biomarkers and Promising Targets to Overcome Tumor Progression
    Fontana, Fabrizio
    Anselmi, Martina
    Limonta, Patrizia
    CANCERS, 2022, 14 (07)
  • [43] Editorial: New insights into prostate cancer: new biomarkers, molecular mechanisms, and therapeutic approaches
    Perri, Anna
    Rago, Vittoria
    Maya-Nunez, Guadalupe
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [44] Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review
    Maekawa, Shigekatsu
    Takata, Ryo
    Obara, Wataru
    CANCERS, 2024, 16 (03)
  • [45] DNA Damage Repair and Current Therapeutic Approaches in Gastric Cancer: A Comprehensive Review
    Wang, Menghui
    Xie, Chuan
    FRONTIERS IN GENETICS, 2022, 13
  • [46] Mechanisms of Disease: biomarkers and molecular targets from microarray gene expression studies in prostate cancer
    Cooper, Colin S.
    Campbell, Colin
    Jhavar, Sameer
    NATURE CLINICAL PRACTICE UROLOGY, 2007, 4 (12): : 677 - 687
  • [47] Mechanisms of Disease: biomarkers and molecular targets from microarray gene expression studies in prostate cancer
    Colin S Cooper
    Colin Campbell
    Sameer Jhavar
    Nature Clinical Practice Urology, 2007, 4 : 677 - 687
  • [48] New molecular approaches for identifying novel targets, mechanisms, and biomarkers for prostate cancer chemopreventive agents
    Williams, ED
    Brooks, JD
    UROLOGY, 2001, 57 (4A) : 100 - 102
  • [49] ATR and p-ATR are emerging prognostic biomarkers and DNA damage response targets in ovarian cancer
    Feng, Wenlong
    Dean, Dylan C.
    Hornicek, Francis J.
    Wang, Jinglu
    Jia, Yanyan
    Duan, Zhenfeng
    Shi, Huirong
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [50] The 5-WS of targeting DNA-damage repair (DDR) pathways in prostate cancer
    Guida, Annalisa
    Mosillo, Claudia
    Mammone, Giulia
    Caserta, Claudia
    Sirgiovanni, Grazia
    Conteduca, Vincenza
    Bracarda, Sergio
    CANCER TREATMENT REVIEWS, 2024, 128